Lysophosphatidic acid inhibits serum deprivation-induced autophagy in human prostate cancer PC-3 cells

Autophagy. 2007 May-Jun;3(3):268-70. doi: 10.4161/auto.3909. Epub 2007 May 25.

Abstract

Lysophosphatidic acid (LPA) is a platelet-enriched bioactive lysophospholipid. By binding to its cognitive G protein-coupled receptors, which are encoded by endothelial differentiation genes (edgs), LPA regulates various cellular activities including proliferation, survival, and migration. Currently, little is known about the influences of LPA on autophagy, a pivotal mechanism for cell survival during conditions of starvation. Herein we present data indicating that LPA attenuates starvation-induced autophagy, by monitoring the percentage of LC3-II, an autophagy indicator, in human prostate PC-3 cells. In addition, by using cells stably expressing EGFP-LC3, LPA is shown to inhibit the formation of autophagosomes in serum-starved conditions. Our results suggest that in these conditions, LPA inhibits autophagy, which might facilitate early cancer development.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autophagy / drug effects*
  • Cell Line, Tumor
  • Culture Media, Serum-Free
  • Humans
  • Lysophospholipids / pharmacology*
  • Male
  • Microtubule-Associated Proteins / metabolism
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology
  • Receptors, G-Protein-Coupled / metabolism

Substances

  • Culture Media, Serum-Free
  • Lysophospholipids
  • MAP1LC3A protein, human
  • Microtubule-Associated Proteins
  • Receptors, G-Protein-Coupled
  • lysophosphatidic acid